Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women

Journal of Bone and Mineral Research

Volumn 29, Issue 4, 2014, Pages 935-943

  Mccolm, Juliet ^a   Hu, Leijun ^a   Womack, Theresa ^a   Tang, Cheng Cai ^b   Chiang, Alan Y ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Eli Lilly Singapore Pte Ltd   (Singapore)

Author keywords

ANABOLICS; BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIALS; DXA; OSTEOPOROSIS

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; BLOSOZUMAB; CALCIUM; COLLAGEN TYPE 1; DRUG ANTIBODY; OSTEOCALCIN; PARATHYROID HORMONE; PLACEBO; PROCOLLAGEN C PROTEINASE; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; SOST PROTEIN, HUMAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE TURNOVER; CALCIUM URINE LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; LUMBAR SPINE; MIDDLE AGED; NAUSEA; NORMAL HUMAN; NOSE OBSTRUCTION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; CLINICAL TRIAL; GENETIC MARKER; IMMUNOLOGY; MULTICENTER STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; FEMALE; GENETIC MARKERS; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 84897586287     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2092     Document Type: Article

References (12)

1. Poole KE, van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 13: 1842-4.
2. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 6: 805-14.
3. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 5: 537-43.
4. Brunkow ME, Gardner JC, Van NJ, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 3: 577-89.
5. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab. 2003; 12: 5778-83.
6. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 6: 860-9.
7. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 12: 2647-56.
8. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 5: 948-59.
9. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 1: 19-26.
10. Ma YL, Page T, Zeng QQ, et al., Blosozumab, a humanized monoclonal antibody, and a chimeric rodent monoclonal antibody against sclerostin robustly increase bone formation activity in intact monkeys and ovariectomized rats. J Bone Miner Res. 2012;(Suppl 1):Available at http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx?aid=580ec783-5e46-4f61-bb0d-0b63f8ee361d. Accessed December 10, 2012.
11. Hampson G, Fogelman I., Clinical role of bisphosphonate therapy. Int J Womens Health. 2012; 4: 455-69.
12. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008; 3: 852-60.